Evidence map›Paper›PMID 33006741›Full record

ArticleDrug delivery and translational research2021

A multicomponent-based microemulsion for boosting ovarian cancer therapy through dual modification with transferrin and SA-R

Haijun Zhao, Mengyuan Chen, Zhujiang Zhao, Linjia Zhu, Shaofei Yuan

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Comprehensive Analysis of Tripterine Anti-Ovarian Cancer Effects Using Weighted Gene Co-Expression Network Analysis and Molecular Docking.Medical science monitor : international medical journal of experimental and clinical research · 2022
    Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Haijun ZhaoDepartment of Obstetrics and Gynecology, Zhongda Hospital, Medical School of Southeast University, Nanjing, 210009, People's Republic of China.
Mengyuan ChenDepartment of Obstetrics and Gynecology, Zhongda Hospital, Medical School of Southeast University, Nanjing, 210009, People's Republic of China.
Zhujiang ZhaoDepartment of Medical Genetics and Developmental Biology, Medical School of Southeast University, Nanjing, 210009, People's Republic of China. zhujiangzhao@seu.edu.cn.
Linjia ZhuDepartment of Medical Oncology, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325200, People's Republic of China.
Shaofei YuanDepartment of Medical Oncology, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325200, People's Republic of China. yuanshaofeitg@126.com.ORCID 0000-0002-8065-376X
Wenzhou Medical University · CNZhongda Hospital Southeast University · CNSoutheast University · BD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Balancing the antitumor activity and systemic toxicity of tripterine still faces a big challenge due to the narrow therapeutic window. To address this issue, we report a microemulsion system based on tripterine, brucea oil, and glycyrrhizin, and dual modified with both transferrin and cell-penetrating peptide SA-R

Indexed as

Cell-Penetrating PeptidesCoixOvarian NeoplasmsCell Line, TumorEmulsionsHumansTransferrinCell-Penetrating PeptidesEmulsionsTransferrinBrucea oilCombinational therapyOvarian cancerSA-R6H4 cell-penetrating peptideTargeted drug deliveryTripterine

Identifiers

PMID33006741
OpenAlexW3090667539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.